Top Story

Top Takeaways from ASH: Mutations in MDS, AML impact prognosis, spur development of novel agents

Top Takeaways from ASH: Mutations in MDS, AML impact prognosis, spur development of novel agents
May 30, 2016

Findings presented at the ASH Annual Meeting and Exposition contribute to the growing body of literature that demonstrates a correlation between specific gene mutations and prognosis among patients with acute myeloid leukemia and myelodysplastic syndrome. Opinions are mixed in regard to how the evidence could impact scoring systems used to classify patients, which currently do not consider these mutations, but experts agree that the evidence promotes the development of new therapeutic agents.

“There is a wealth of emerging information that demonstrates that specific mutations in MDS are associated with prognosis, inside and outside the context of allogeneic hematopoietic stem cell transplantation,” William A. Wood, MD, of the Leukemia, Lymphoma and Myeloma Program and the Bone Marrow and Stem Cell Transplantation Program at the University of North Carolina School of Medicine, told Healio.com. “Further, the presence of these mutations may contribute independent prognostic information in addition to what is already known through the most commonly used prognostic scoring systems in this disease.”

Model used to estimate link between radiation, cancer must be re-evaluated

May 29, 2016
Previous investigations conducted by the founders of the linear no-threshold model with respect to genetic effects and carcinogenesis represent “one of the…

Five updates for World Blood Cancer Day

May 28, 2016
DKMS, an international nonprofit organization, founded World Blood Cancer Day in 2014.World Blood Cancer Day — observed on May 28 — is designed to raise…
In the Journals

Economic crisis, unemployment rates drive excess cancer deaths

May 27, 2016
The 2008 to 2010 global economic crisis appeared associated with 260,000 excess cancer deaths in member states of the Organization for Economic Cooperation and…
In the Journals

OS comparable between Dovitinib, Nexavar for advanced HCC

May 27, 2016
The overall survival and safety rates were similar between patients with advanced hepatocellular carcinoma treated with Dovitinib vs. Nexavar, according to published…
More News Headlines »

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »

VIDEO: Midostaurin, other agents represent therapeutic advances for AML

May 9, 2016
More »
AACR Annual Meeting

AACR Annual Meeting

CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today